ICD-10-CM Billable Code

C83.1

Mantle cell lymphoma

Clinical Classification Guidelines

Inclusion Terms

  • Centrocytic lymphoma
  • Malignant lymphomatous polyposis

Medical Intelligence & Overview

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that originates from B-cells located in the 'mantle zone' of lymph nodes. It is considered an aggressive cancer but can sometimes progress more slowly. This lymphoma typically affects adults and is characterized by abnormal growth of lymphoid tissue within lymph nodes. Recognition of the disease's features and understanding its progression can help in managing health effectively. Although MCL shares features with other lymphomas, it has distinctive cellular and genetic characteristics, such as overexpression of the cyclin D1 protein, which are essential for diagnosis and treatment planning.

Causes & Symptoms

Clinical Causes: Genetic mutations, particularly the translocation t(11;14)(q13;q32), which leads to overproduction of cyclin D1 Age-related genetic changes, predominantly affecting individuals over 60 years Potential environmental exposures, although specific factors are not well-established Family history of lymphoma or other hematological malignancies (rare)

Key Symptoms: Swollen lymph nodes, often painless and occurring in the neck, armpits, or groin Unexplained weight loss Persistent fatigue or weakness Fever and night sweats Abdominal pain or fullness due to enlarged spleen or lymph nodes Frequent infections owing to a compromised immune system

Diagnostic & Treatment

Diagnosis Path: Diagnosing mantle cell lymphoma involves a combination of clinical evaluation, laboratory tests, and tissue analysis. Key diagnostic steps include: - Physical examination to identify swollen lymph nodes or organ enlargement - Blood tests to assess general health and look for abnormal cells - Imaging studies, such as CT scans or PET scans, to determine the extent of disease - Biopsy of affected lymph nodes or other tissues to examine the cellular structure and confirm the presence of malignant cells - Immunohistochemistry testing to identify the expression of specific proteins like cyclin D1 - Genetic testing to detect characteristic chromosomal translocations associated with MCL This comprehensive approach helps distinguish mantle cell lymphoma from other types of lymphomas and guides treatment decisions.

Treatment Protocols: Treatment options for mantle cell lymphoma depend on factors such as disease stage, patient's age, and overall health. Common therapies include: - Chemotherapy regimens that may incorporate monoclonal antibody therapies, such as rituximab - Targeted therapies designed to interfere with cellular pathways specific to MCL - Immunotherapy approaches to enhance the body's immune response against cancer cells - Stem cell or bone marrow transplantation in suitable candidates - Supportive care measures to manage symptoms and reduce side effects Prognosis varies among individuals, with ongoing research aiming to improve outcomes and develop new treatment strategies.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C83.1 a billable ICD-10 code?
Yes, C83.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C83.1?
Clinical documentation must specify the nature of Mantle cell lymphoma and any associated comorbidities for accurate reporting.

Cite this Clinical Reference